Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K5EI
|
|||
| Former ID |
DNC009010
|
|||
| Drug Name |
Naphthalen-2-yl cyclohexylcarbamate
|
|||
| Synonyms |
naphthalen-2-yl cyclohexylcarbamate; CHEMBL77250; NSC204269; AC1L796V; SCHEMBL1690685; ZINC1738803; BDBM50128573; naphthalen-2-yl N-cyclohexylcarbamate; NSC-204269; Cyclohexyl-carbamic acid naphthalen-2-yl ester; US8815951, 110
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H19NO2
|
|||
| Canonical SMILES |
C1CCC(CC1)NC(=O)OC2=CC3=CC=CC=C3C=C2
|
|||
| InChI |
1S/C17H19NO2/c19-17(18-15-8-2-1-3-9-15)20-16-11-10-13-6-4-5-7-14(13)12-16/h4-7,10-12,15H,1-3,8-9H2,(H,18,19)
|
|||
| InChIKey |
ZYHUWMGJJOBBCF-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.